For the full year, QuantumScape's net loss widened from $430 million to $475 million. That situation might seem grim for a company with an enterprise value (EV) of $2.2 billion, but it also provided ...

Qure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy ...

If you want to know who really controls uniQure N.V. (NASDAQ:QURE), then you'll have to look at the makeup of its share registry. With 66% stake, institutions possess the maximum shares in the company ...

Abundant catalysts, including the rise of artificial intelligence, stock splits, and Donald Trump's return to the White House, have sent the Dow Jones Industrial Average, S&P 500, and Nasdaq ...

No patients returned to continuous prophylaxis between year three and year four. There were no serious adverse events related to treatment. Price Action: QURE stock is down 5.95% at $15.25 at last ...

Shares of uniQure (NASDAQ:QURE – Get Free Report) have received a consensus rating of “Buy” from the ten ratings firms that are presently covering the company, Marketbeat.com reports. Two investment ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

uniQure N.V. announced the completion of enrollment for the first cohort of its Phase I/IIa trial for AMT-191, a gene therapy aimed at treating Fabry disease. The Independent Data Monitoring ...